Whitehawk Therapeutics Q2 net loss narrows
WHWK•Quarterly results
- US oncology therapeutics firm's Q2 net loss narrowed
- Q2 operating loss also narrowed
- Lower R&D expenses drove improved results; prior year included $38 mln license fee
Lower R&D expenses drove the improvement, with research and development expenses falling due to the absence of the prior year's $38 mln license fee.
Key details and analyst coverage
| Metric | Beat/Miss | Actual | Consensus Estimate |
| Q2 Net Loss | Beat | $16.64 mln | $22.29 mln (7 Analysts) |
| Q2 Operating Income | Beat | -$18.11 mln | -$23.48 mln (6 Analysts) |
| Q2 Pretax Loss | Beat | $16.64 mln | $22.88 mln (6 Analysts) |
| Q2 Operating Expenses | $18.11 mln |
- The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell"
- The average consensus recommendation for the pharmaceuticals peer group is "buy"
- Wall Street's median 12-month price target for Whitehawk Therapeutics Inc is $7.50, about 84.3% above its August 5 closing price of $4.07
